Guidant Looking Beyond Boston Scientific's Paclitaxel Stent Dispute
This article was originally published in The Gray Sheet
Executive Summary
Cook's ability to establish Guidant as a "distributor" rather than a licensee of its paclitaxel application technology should result in a favorable outcome in the drug-coated stent dispute brought by Boston Scientific, Guidant claims.